Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00348816 · ClinicalTrials.gov registry record · Phase 2
Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00348816 is a Phase 2 study that was terminated before completion, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 21 participants.
The verdict
NCT00348816, a Phase 2 study, was terminated before completion, sponsored by The University of Texas Health Science Center at San Antonio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Docetaxel may make tumor cells more sensitive to radiation therapy. Giving docetaxel together with radiation therapy and prednisone after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well giving docetaxel together with radiation therapy and prednisone works in treating patients who have undergone surgery for prostate cancer.
Interventions
- DRUG prednisone
- RADIATION Radiation therapy
- DRUG docetaxel
- PROCEDURE Radical prostatectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2006-05 |
| Est. Completion | 2016-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00348816
The ClinicalTrials.gov registry entry for NCT00348816 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which prednisone is the first listed.
NCT00348816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00348816 about?
NCT00348816 is a clinical study titled "Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer". RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Docetaxel may make tumor cells more sensiti...
What is the current status of trial NCT00348816?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2006-05. Estimated completion is 2016-07-08.
What interventions are being tested in trial NCT00348816?
The interventions under investigation include: prednisone (DRUG), Radiation therapy (RADIATION), docetaxel (DRUG), Radical prostatectomy (PROCEDURE).
Who is sponsoring clinical trial NCT00348816?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.